• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤完全切除后抗原交叉呈递的丧失与保护性肿瘤特异性CD8(+) T细胞免疫的产生有关。

Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity.

作者信息

Brown Matthew D, van der Most Robbert, Vivian Justin B, Lake Richard A, Larma Irma, Robinson Bruce W S, Currie Andrew J

机构信息

Urological Research Centre/University Department of Surgery; Sir Charles Gairdner Hospital; Perth, WA.

出版信息

Oncoimmunology. 2012 Oct 1;1(7):1084-1094. doi: 10.4161/onci.20924.

DOI:10.4161/onci.20924
PMID:23170256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3494622/
Abstract

An incomplete understanding on the effect of surgery on tumor-specific immunity continues to hamper efforts to combine surgery with immunotherapy in the clinic. Herein, we describe the impact of tumor resection on the tumor-specific T-cell response, showing that complete tumor resection is associated with (1) a decline in the amount of cross-presented tumor antigens, (2) a decline of cytolytic tumor-specific CD8(+) T cell activity, and (3) the development of systemic CD8(+) T cell-mediated protective immunity. Our findings are consistent with a model whereby tumor resection releases antitumor CD8(+) T cells from chronic antigen exposure, allowing a gradual differentiation toward functional antitumor memory T cells. This process depends on sentinel lymph nodes, as their removal at the time of surgery was associated with a strong negative effect on survival. We conclude that complete tumor resection provides a unique environment that boosts protective immunological memory and might provide a powerful platform for immunotherapy. Our findings also carry important implications for the design and timing of post-surgery immunotherapeutic regimens.

摘要

对手术对肿瘤特异性免疫影响的不完全理解,持续阻碍着临床上将手术与免疫疗法相结合的努力。在此,我们描述了肿瘤切除对肿瘤特异性T细胞反应的影响,表明完整的肿瘤切除与以下情况相关:(1)交叉呈递的肿瘤抗原数量下降;(2)细胞溶解性肿瘤特异性CD8(+) T细胞活性下降;(3)全身性CD8(+) T细胞介导的保护性免疫的发展。我们的研究结果与一种模型一致,即肿瘤切除使抗肿瘤CD8(+) T细胞从慢性抗原暴露中释放出来,使其逐渐分化为功能性抗肿瘤记忆T细胞。这一过程依赖于哨兵淋巴结,因为手术时切除哨兵淋巴结对生存有强烈的负面影响。我们得出结论,完整的肿瘤切除提供了一个独特的环境,可增强保护性免疫记忆,并可能为免疫疗法提供一个强大的平台。我们的研究结果对术后免疫治疗方案的设计和时机也具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/1e77e2eb473d/onci-1-1084-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/4503de9933a3/onci-1-1084-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/9e9298136f92/onci-1-1084-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/1e77e2eb473d/onci-1-1084-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/4503de9933a3/onci-1-1084-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/9e9298136f92/onci-1-1084-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e28c/3494622/1e77e2eb473d/onci-1-1084-g6.jpg

相似文献

1
Loss of antigen cross-presentation after complete tumor resection is associated with the generation of protective tumor-specific CD8(+) T-cell immunity.肿瘤完全切除后抗原交叉呈递的丧失与保护性肿瘤特异性CD8(+) T细胞免疫的产生有关。
Oncoimmunology. 2012 Oct 1;1(7):1084-1094. doi: 10.4161/onci.20924.
2
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.尽管人类转移性黑色素瘤对自身抗原有抗肿瘤免疫,但肿瘤部位缺乏终末分化的肿瘤特异性CD8 + T细胞。
Cancer Res. 2003 May 15;63(10):2535-45.
3
Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.术前射频消融的免疫佐剂活性可预防侵袭性小鼠结直肠癌的局部和全身复发。
PLoS One. 2015 Nov 23;10(11):e0143370. doi: 10.1371/journal.pone.0143370. eCollection 2015.
4
Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.重组脂化 Survivin 通过抗原呈递细胞的有效摄取引发抗原交叉呈递和抗肿瘤免疫。
Front Immunol. 2018 Apr 23;9:822. doi: 10.3389/fimmu.2018.00822. eCollection 2018.
5
Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.在BALB/c小鼠中,猿猴病毒40大T抗原特异性排斥mKSA肿瘤细胞严重依赖于严格肿瘤相关、肿瘤特异性的CD8(+) 细胞毒性T淋巴细胞和CD4(+) T辅助细胞。
J Virol. 2001 Nov;75(22):10593-602. doi: 10.1128/JVI.75.22.10593-10602.2001.
6
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.白细胞介素-2瘤内免疫疗法增强介导肿瘤细胞和肿瘤相关血管破坏的CD8 + T细胞:白细胞介素-2的一种新机制。
J Immunol. 2003 Nov 15;171(10):5051-63. doi: 10.4049/jimmunol.171.10.5051.
7
Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8 T cells.经工程改造表达膜结合抗原的外膜囊泡可对树突状细胞进行交叉呈递,以激活 CD8 T 细胞。
Acta Biomater. 2019 Jun;91:248-257. doi: 10.1016/j.actbio.2019.04.033. Epub 2019 Apr 17.
8
Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.基于记忆T细胞的过继性免疫疗法在小鼠中增强局部和全身抗黑色素瘤CD8 + T细胞反应。
Cancer Immunol Immunother. 2016 May;65(5):601-11. doi: 10.1007/s00262-016-1823-8. Epub 2016 Mar 24.
9
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.源自中央记忆细胞而非经肿瘤特异性 TCR 基因修饰的 CD8(+)T 细胞的人类效应 T 细胞,具有用于过继免疫治疗的优越特性。
Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.
10
Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.肿瘤消融术联合 CpG 和皂角苷佐剂可影响肿瘤引流淋巴结中 IL-1 的产生和多功能 T 细胞数量。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000649.

引用本文的文献

1
Prognostic significance of soluble PD-L1 in prostate cancer.可溶性 PD-L1 在前列腺癌中的预后意义。
Front Immunol. 2024 Jul 11;15:1401097. doi: 10.3389/fimmu.2024.1401097. eCollection 2024.
2
Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.阑尾和结直肠癌腹膜疾病的减瘤手术(CRS)及腹腔热灌注化疗(HIPEC)的当前趋势
J Clin Med. 2022 May 18;11(10):2840. doi: 10.3390/jcm11102840.
3
Immunophenotype Rearrangement in Response to Tumor Excision May Be Related to the Risk of Biochemical Recurrence in Prostate Cancer Patients.

本文引用的文献

1
Tumor antigen cross-presentation and the dendritic cell: where it all begins?肿瘤抗原交叉呈递与树突状细胞:一切从何开始?
Clin Dev Immunol. 2010;2010:539519. doi: 10.1155/2010/539519. Epub 2010 Oct 13.
2
Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis.激活的 CD8+ T 效应/记忆细胞通过 FasL 介导的细胞凋亡从肿瘤中消除 CD4+ CD25+ Foxp3+ T 调节细胞。
J Immunol. 2009 Dec 15;183(12):7656-60. doi: 10.4049/jimmunol.0902625.
3
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.
免疫表型重排对肿瘤切除的反应可能与前列腺癌患者生化复发风险相关。
J Clin Med. 2021 Aug 20;10(16):3709. doi: 10.3390/jcm10163709.
4
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used.肿瘤引流淋巴结产生的 CD8 T 细胞在原发性肿瘤切除后控制肺转移中发挥作用,但在辅助免疫治疗时不起作用。
Cancer Immunol Immunother. 2021 Nov;70(11):3249-3258. doi: 10.1007/s00262-021-02934-3. Epub 2021 Apr 9.
5
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial.局部区域治疗对晚期铂类难治性头颈癌患者接受纳武利尤单抗治疗反应的影响:NEED试验
Vaccines (Basel). 2020 Apr 20;8(2):191. doi: 10.3390/vaccines8020191.
6
Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome.引流淋巴结中的预处理肿瘤新抗原反应并不常见,但可预测检查点阻断治疗的结果。
Oncoimmunology. 2019 Nov 7;9(1):1684714. doi: 10.1080/2162402X.2019.1684714. eCollection 2020.
7
A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer.手术去负荷以改善非小细胞肺癌抗 PD-1 治疗效果的原理。
Sci Rep. 2019 Nov 15;9(1):16902. doi: 10.1038/s41598-019-52913-z.
8
Neo-antigen specific T cell responses indicate the presence of metastases before imaging.新抗原特异性 T 细胞反应可在影像学检查前提示转移灶的存在。
Sci Rep. 2019 Oct 10;9(1):14640. doi: 10.1038/s41598-019-51317-3.
9
Restoration of defective cross-presentation in tumors by gemcitabine.通过吉西他滨恢复肿瘤中的缺陷交叉呈递。
Oncoimmunology. 2015 Feb 25;4(5):e1005501. doi: 10.1080/2162402X.2015.1005501. eCollection 2015 May.
10
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.手术前进行新辅助抗肿瘤疫苗接种可提高生存率。
J Transl Med. 2014 Sep 4;12:245. doi: 10.1186/s12967-014-0245-7.
环磷酰胺化疗使肿瘤细胞对 TRAIL 依赖性 CD8 T 细胞介导的免疫攻击敏感,从而抑制肿瘤生长。
PLoS One. 2009 Sep 10;4(9):e6982. doi: 10.1371/journal.pone.0006982.
4
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.源自中枢记忆细胞的效应性CD8 + T细胞的过继转移在灵长类动物中建立了持久的T细胞记忆。
J Clin Invest. 2008 Jan;118(1):294-305. doi: 10.1172/JCI32103.
5
Forkhead box P3-positive regulatory T cells in immune surveillance and cancer.免疫监视与癌症中的叉头框蛋白P3阳性调节性T细胞
Br J Cancer. 2007 Oct 8;97(7):1015-6; author reply 1017-8. doi: 10.1038/sj.bjc.6603939. Epub 2007 Aug 14.
6
Tumor-driven evolution of immunosuppressive networks during malignant progression.恶性进展过程中免疫抑制网络的肿瘤驱动进化。
Cancer Res. 2006 Jun 1;66(11):5527-36. doi: 10.1158/0008-5472.CAN-05-4128.
7
Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.重组粒细胞-巨噬细胞集落刺激因子加自体肿瘤细胞作为间皮瘤患者的疫苗。
Lung Cancer. 2006 May;52(2):189-97. doi: 10.1016/j.lungcan.2006.01.007. Epub 2006 Mar 24.
8
Human T cell responses against melanoma.人类T细胞对黑色素瘤的反应。
Annu Rev Immunol. 2006;24:175-208. doi: 10.1146/annurev.immunol.24.021605.090733.
9
Restoring function in exhausted CD8 T cells during chronic viral infection.在慢性病毒感染期间恢复耗竭的CD8 T细胞的功能。
Nature. 2006 Feb 9;439(7077):682-7. doi: 10.1038/nature04444. Epub 2005 Dec 28.
10
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.部分而非完全的肿瘤减瘤手术与化疗及辅助免疫治疗联合应用时可促进保护性抗肿瘤记忆。
Cancer Res. 2005 Sep 1;65(17):7580-4. doi: 10.1158/0008-5472.CAN-05-0328.